Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Menlo Advisors LLC

Menlo Advisors LLC lowered its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 9.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 133,235 shares of the biopharmaceutical company's stock after selling 14,650 shares during the period. Royalty Pharma accounts for 1.7% of Menlo Advisors LLC's investment portfolio, making the stock its 20th largest position. Menlo Advisors LLC's holdings in Royalty Pharma were worth $3,398,000 as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in the stock. Raymond James Financial Inc. purchased a new stake in shares of Royalty Pharma in the 4th quarter valued at approximately $19,990,000. New South Capital Management Inc. lifted its holdings in Royalty Pharma by 19.9% in the fourth quarter. New South Capital Management Inc. now owns 2,957,125 shares of the biopharmaceutical company's stock valued at $75,436,000 after acquiring an additional 490,754 shares during the last quarter. Arizona State Retirement System grew its position in Royalty Pharma by 0.5% in the fourth quarter. Arizona State Retirement System now owns 110,637 shares of the biopharmaceutical company's stock worth $2,822,000 after acquiring an additional 537 shares during the period. Proficio Capital Partners LLC acquired a new stake in Royalty Pharma during the fourth quarter worth $786,000. Finally, M&T Bank Corp raised its position in Royalty Pharma by 25.2% in the fourth quarter. M&T Bank Corp now owns 23,467 shares of the biopharmaceutical company's stock valued at $599,000 after purchasing an additional 4,718 shares during the period. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Royalty Pharma Trading Down 0.8 %

Shares of NASDAQ RPRX traded down $0.26 during trading on Monday, reaching $32.75. The stock had a trading volume of 5,287,537 shares, compared to its average volume of 2,821,426. The business's 50-day moving average price is $30.87 and its 200-day moving average price is $28.41. Royalty Pharma plc has a fifty-two week low of $24.05 and a fifty-two week high of $34.20. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The company has a market cap of $18.88 billion, a P/E ratio of 22.59, a PEG ratio of 2.31 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, equities research analysts predict that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 21st will be issued a $0.22 dividend. This is a boost from Royalty Pharma's previous quarterly dividend of $0.21. The ex-dividend date of this dividend is Friday, February 21st. This represents a $0.88 annualized dividend and a dividend yield of 2.69%. Royalty Pharma's dividend payout ratio is presently 60.69%.

Wall Street Analysts Forecast Growth

Separately, TD Cowen upgraded Royalty Pharma to a "strong-buy" rating in a report on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $41.60.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.